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Syphilis prevalence trends in 
adult women in 132 countries – 
estimations using the Spectrum 
Sexually Transmitted Infections 
model
Eline L. Korenromp1, S. Guy Mahiané2, Nico Nagelkerke3, Melanie M. Taylor4,5, 
Rebecca Williams6, R. Matthew Chico6, Carel Pretorius2, Laith J. Abu-Raddad  7 & 
Jane Rowley8
We estimated national-level trends in the prevalence of probable active syphilis in adult women using 
the Spectrum Sexually Transmitted Infections (STI) model to inform program planning, target-setting, 
and progress evaluation in STI control. The model fitted smoothed-splines polynomial regressions to 
data from antenatal clinic surveys and screening and representative household surveys, adjusted for 
diagnostic test performance and weighted by national coverage. Eligible countries had ≥1 data point 
from 2010 or later and ≥3 from 2000 or later from adult populations considered representative of the 
general female population (pregnant women or community-based studies). Between 2012 and 2016, 
the prevalence of probable active syphilis in women decreased in 54 (41%) of 132 eligible countries; 
this decrease was substantive (≥10% proportionally, ≥0.10% percentage-point absolute difference 
and non-overlapping 95% confidence intervals in 2012 and 2016) in 5 countries. Restricting eligible 
data to prevalence measurements of dual treponemal and non-treponemal testing limited estimates 
to 85 countries; of these, 45 countries (53%) showed a decrease. These standardized trend estimates 
highlight the need for increased investment in national syphilis surveillance and control efforts if the 
World Health Organization target of a 90% reduction in the incidence of syphilis between 2018 and 2030 
is to be met.
Syphilis is an infection caused by the spirochete Treponema pallidum. It can be transmitted through sexual activity 
and from a mother to fetus vertically during pregnancy or newborn during childbirth. When untreated, syphilis 
causes substantial morbidity and mortality, not only in adults, but also in infants and young children as congenital 
syphilis.
Many countries have committed to reducing rates of adult syphilis, and to eliminating congenital syphilis. The 
World Health Organization (WHO) “Global Health Sector Strategy on Sexually Transmitted Infections (STIs) 
2016–2021” has two syphilis related targets1,2: a 90% reduction in Treponema pallidum incidence globally between 
2018 and 2030, and 50 or fewer cases of congenital syphilis per 100,000 live births in 80% of countries. Monitoring 
progress toward these targets is hampered by the quality and quantity of national data. Many national programs 
lack an estimate of their current burdens of adult and congenital syphilis, compromising not only progress evalu-
ation but also target-setting, program planning, and costing3.
The WHO produces global and regional syphilis prevalence and incidence estimates for adult women roughly 
every four years. The most recent estimates were for 2012, when WHO estimated that the global prevalence of 
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syphilis in adult men and women were 0.49% (0.4–0.6%) and 0.48 (0.3–0.7%) and there were 350,000 adverse 
pregnancy outcomes in infected pregnant women4. The Institute of Health Metrics and Evaluation (IHME) also 
estimated syphilis burdens5. However, to date, there has been no systematic exploration of country-level trends.
The Spectrum Sexually Transmitted Infections (STI) model (Spectrum-STI) was incorporated into the 
Spectrum suite of health policy models in 2016 as a tool that countries can use to estimate trends in the prev-
alence and incidence of syphilis, gonorrhea and chlamydia6–8. The model estimates national adult prevalence 
trends by fitting statistical models to prevalence data, adjusted for diagnostic test performance and weighted by 
national coverage.
In this paper, the Spectrum-STI model and the Spectrum syphilis database were used to examine trends over 
time in the prevalence of probable active syphilis in women 15 to 49 years of age between 2012 and 2016. The 
focus of the paper is on the methods and estimates of trends across countries and cross-country patterns in data 
availability, but not on the results for individual countries. The paper also explores how data eligibility criteria and 
statistical methods influence the estimates.
Methods
Spectrum-STI model. The basic structure of the Spectrum-STI model has been described6. Some refine-
ments have been made to the model since the initial country applications:
 1. Prevalence data are fitted to calendar year using segmented, second-order polynomial spline regres-
sions9–11, with a maximum of two knots rather than a simple logistic regression (Supplementary Informa-
tion 1(SI1)). This allows for up to three historic phases or trends in a country’s prevalence of syphilis.
 2. Prevalence is fitted through the corresponding incidence rate (SI1). The constraint that incidence must 
be ≥0 in any year ensures that there are no unrealistic sharp falls in prevalence from one year to the 
next, which would be inconsistent with epidemiologically valid incidence rates and average duration of 
infection.
 3. A random effects component has been included to account for heterogeneity across prevalence measure-
ments within a country owing to the variability in prevalence measures due to variations in the sampled 
study population, other than sampling variation. Prevalence estimates were resampled following beta 
distributions, to which noise was added in the logit scale and simulated as a function of the population 
sampled to account for uncertainty and possible biases associated with pooling prevalence data across 
study populations (surveys in Antenatal Care clinics (ANC), routine ANC screening, adult women not 
in antenatal care, adult men, and adult men and women without sex disaggregation). This guards against 
over-interpreting fluctuations between successive data points reflecting unaccounted sources of variation, 
including reporting errors, in the data.
 4. Prevalence time trends were extrapolated to two years after the latest national data point, and to two years 
before the first available national data point. For earlier and later years, prevalence was assumed to be con-
stant at the earliest and latest estimates.
Infection episode durations, used to inform the relationship between incidence and prevalence, were taken 
as assumed in the WHO’s 2012 global syphilis estimations4: Weighted between treated and untreated episodes, 
the weighted duration was set at 1.28 years in countries with good STI treatment access (high income countries), 
2.42 years in countries with moderate access (South and Central Americas and the Caribbean, Oceania, East and 
Central Asia, Central Europe, Eastern Mediterranean) and 4.13 years in countries with poor access (sub-Saharan 
Africa, and South and South-East Asia). Each of these values was assumed to have a standard error of ±50%.
As in the original 2016 model, estimated prevalence was constrained to a maximum value of 20% for all years 
and all countries to avoid extrapolations to overly high (and unrealistic) prevalence values. The 20% maximum 
value was based on available data from low- and middle-income countries since 19904,12.
Statistical analyses were carried out in R version 3.4.013. Bootstrapping (400 replications) was used to gen-
erate uncertainty bounds6. In each bootstrap iteration, three sets of variables were resampled: prevalence data, 
diagnostic test adjustment values, and duration of infection. The fitting procedure was applied to the simulated/
bootstrapped data, and confidence intervals (CIs) were derived using the percentile method.
Spectrum syphilis database. The Spectrum-STI global syphilis database is a comprehensive compilation 
of syphilis prevalence data from a number of sources including the Global AIDS Monitoring system (GAM) 
database14, databases compiled by WHO and by IHME, data identified from other literature reviews12,14–21 and 
data shared during country applications of the Spectrum-STI tool22–27 (see details in SI2). The version used in the 
present analysis includes data identified and compiled as of 2nd May 2018.
The analysis in this paper is based on the subset of the studies in the database that met the following criteria: 
(i) the population could be considered representative of the general population (e.g. pregnant women, women at 
delivery, women attending family planning clinics, and individuals selected for participation in a Demographic 
and Health Survey); (ii) specimens were collected between 1990 and 2016, and (iii) syphilis was diagnosed 
using either a non-treponemal or treponemal serological test, or both. Studies conducted among the following 
non-representative groups were excluded: patients seeking care for an STI or genital symptoms, women with 
abnormal Papanicolaou smears, women attending gynaecology or sexual health clinics, remote or indigenous 
populations, men who have sex with men (MSM), and female sex workers (FSW).
All duplicate data points were removed. Studies with a reported prevalence of 0% were approximated as 1 case 
divided by 100 times the sample size in order to facilitate the estimation of uncertainty intervals. For studies that 
provided data for two or more years the data were entered separately by calendar year and each year was counted 
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as one data point. When separation by calendar year was not possible, the study was entered as one data point at 
the mid-point of the study period.
In addition, to generate estimates for overall national women’s populations, we increased the weighted prev-
alence estimates by 10% to reflect under-sampling of higher-risk populations in ANC and general population 
surveys, as was done by WHO in their regional and global estimates4.
Adjusting for diagnostic test. All eligible data were adjusted to account for the diagnostic test used in 
the study. We defined probable active syphilis as concurrent positivity on a non treponemal and treponemal test. 
This is the definition recommended and used by the WHO4 and by the IHME5. Prevalence data from studies 
that used either a treponemal or non-treponemal test alone were adjusted using a method described in previ-
ous meta-analyses12,28–30: prevalence values for studies using only treponemal or non-treponemal tests without 
confirmatory tests were multiplied by 0.53 and values from studies where the diagnostic test was unknown by 
0.7515,26–28. Values based on Rapid treponemal-based test were multiplied by 0.70, as these tests are believed to be 
relatively specific compared to conventional treponemal tests6. Each adjustment multiplier was assumed to have 
a standard error of ±25%.
Country eligibility. Prevalence trends were generated for the subset of countries in the Spectrum syphilis 
database that met the study inclusion criteria and had at least one data point post-2010 and three or more data 
points from 2000 or later.
Generating national estimates. All of the data from a country were pooled after adjusting for diagnostic 
tests. When pooling data, the prevalence in pregnant women attending ANC and in adult women in the general 
population4 was assumed to be the same, and the male-to-female ratio was set at 1:1, in keeping with WHO’s 2012 
global estimates4 and supported by a recent global meta-analysis29 of national household and other general pop-
ulation surveys31–33. In addition, it was assumed that all qualifying data were representative, i.e. no adjustments 
were made for possible over-sampling of urban or rural sites, or for urban/rural prevalence differences.
Each data point in a country was assigned a weight to reflect how representative it was of the national popula-
tion (see Table SI3). The weighted prevalence data were scaled within each country by dividing by sample size, so 
that a study’s sample size did not influence the estimated national prevalence level or trend. Sample size, however, 
did influence the uncertainty ranges obtained using bootstrap resampling, as described above.
Time trend analysis. The time trend analysis focused on changes in the median prevalence of active syphilis 
between 2012 and 2016 based on 400 bootstraps per country and on the average annual proportional decline 
between 2012 and 2016. Countries were grouped into four categories according to the change in their median 
estimated prevalence from 2012 to 2016 (proportional as well as absolute, so as to cover the public health signifi-
cance of the change) combined with the precision of the median estimates in those two years:
•	 Substantive decrease: the prevalence decreased, the absolute difference between the median estimated prev-
alence at 2012 and 2016 was ≥10% proportionally, ≥0.05% as a percentage point difference, and the low-
er-bound of the 2012 estimate was above the upper-bound of the 2016 estimate;
•	 Non-substantive decrease: the median estimated prevalence decreased from 2012 to 2016, but the country 
did not meet the criteria above to be classified as substantive decrease;
•	 Substantive increase: the prevalence increased, the absolute difference between the median estimated preva-
lence at 2012 and 2016 was ≥10% proportionally, ≥0.05% as a percentage point, and the upper-bound of the 
2012 estimate was below the lower-bound of the 2016 estimate;
•	 Non-substantive increase: the median estimated prevalence increased from 2012 to 2016, but the country 
did not meet the criteria above to be classified as substantive increase.
We also assessed the average annual proportional decline over 2012 to 2016, relative to the annual decline rate 
that would be expected to meet the WHO global strategy target of 90% reduction from 2018 to 20301.
Sensitivity analysis. Univariate sensitivity analyses were performed to evaluate the influence of key param-
eters, choices and uncertainties, on the estimated median prevalence across the modelled countries in 2012 and 
2016, and on the number of countries in each of the time trend categories. Parameters and choices explored 
included tightening the eligibility criteria for the trend analysis to those studies conducted only in ANC women 
(Scenario A), or requiring studies to have one or more data points from 2012 or later rather than 2011 or later 
(Scenario B). In addition, we explored the effect of reducing the number of years of prevalence data included in 
the analysis to data from 2005 and later (Scenario C) and to restricting the analysis to only those studies with 
results from both a treponemal and non-treponemal test (Scenario D). We also explored a variant statistical 
model where trends were extrapolated to one rather than two years after and before the latest and earliest national 
data point (Scenario E).
Lastly, we looked at the impact of expanding the study entry criteria to include countries with prevalence 
data from routine blood donor screening34–46 (Scenario F). In this scenario, we assessed time trends in countries 
that did not meet the default country eligibility criteria, but that could be estimated if the eligibility criteria were 
expanded to include data from the screening of blood donations from 2011 or later.
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Results
Syphilis prevalence data. The Spectrum-STI syphilis database, as of 02 May 2018, contained one or more 
data points for 186 countries (range per country: 1 to 61 data points; median 6 data points; SI5) that met the study 
entry criteria. Most data were from routine ANC screening (645 of 1,576 data points; 161 million tests out of 268 
million total tests; Table 1), followed by ANC surveys (605 data points, 8.4 million tests). Most studies used dual 
Rapid Plasma Reagin (RPR) and Treponema pallidum hemagglutination assay (TPHA) testing (819 data points, 
109 million tests), followed by tests of unknown type and RPR testing alone.
In all world regions, the number of eligible data points per country had generally increased over time (Fig. 1). 
Most data points were from the WHO African region, while most tests were conducted in WHO Western Pacific 
region (with fewer data points, of a larger sample size on average).
The data included 60 studies with a reported prevalence of 0%, covering 1.88 million samples tested, i.e. 3.8% 
and 0.25% of total data points and samples tested.
National estimates. 132 countries met the criteria for time trend analysis. These 132 countries accounted 
for 78% of the world’s population in 2016.
Figure 2 shows the Spectrum-STI trend estimates for two of the countries where national Spectrum-STI work-
shops have been held22–25. In Morocco (Fig. 2a) prevalence fell between 2000 and 2007, when Morocco rolled-out 
syndromic STI management, and has been increasing slowly since 2007. In Mongolia (Fig. 2b), the prevalence 
increased to 2002, fell slightly between 2002 and 2010 and has been increasing since 2012.
Among the 132 countries, the median national prevalence estimated for 2016 ranged from 0% to 10.0% (as 
median of 400 bootstraps within each country), with an interquartile range of 0.16% to 1.62% and a cross-country 
median (of the 132 country medians) of 0.88%. In 2012 the median national prevalence ranged from 0% to 10.0%, 
the interquartile range was 0.16% to 1.62% and the cross country median was 0.57%.
Figure 3a shows the median national prevalence of active syphilis in 2012 and 2016 for each country by geo-
graphical region. In general, the median prevalence was lowest for countries in the European Region and highest in 
the African Region. However, there was also considerable variability within regions, especially in the Western Pacific 
Region. Figure 3b shows the same results, grouped by the time trend category into which each country fell. The 
prevalence of probable active syphilis between 2012 and 2016 decreased in 54 of the 132 (41%) countries and in 5 of 
these the decrease was substantive. In the 78 countries where prevalence increased, it was substantive in 10 (Fig. 3b).
Of the 54 countries with a decrease, 12 countries (including 4 of the 5 countries where the decrease was sub-
stantive) had a proportional decrease between 2012 and 2016 greater than 54%, the rate corresponding to the 
average decrease required to achieve the WHO-target of a 90% reduction in the incidence of syphilis globally 
between 2018 to 20301.
Average 
year
Number of studies, 
surveys, and years of 
routine ANC screening
Number 
of positive 
samples
Number of 
samples tested
Unweighted 
average 
prevalence (%)
Data type
  ANC routine 2012 645 1,530,591 161,090,586 0.95
  ANC survey 2005 605 113,813 8,422,062 1.35
  Women survey 2003 93 13,006 2,333,441 0.56
  Men survey 2003 78 5,184 247,945 2.09
  Men + Women survey 2005 11 64,659 3,039,211 2.13
  Blood donors, Women 2007 2 3 693 0.43
  Blood donors, Men 2010 12 1,628 250,398 0.65
  Blood donors, Men + Women 2012 130 147,715 92,247,011 0.16
Diagnostic test
  RPR + TPHA 2008 819 652,567 108,529,201 0.60
  TPHA 2006 71 107,382 12,299,956 0.87
  RPR 2007 353 592,635 42,606,321 1.39
  Rapid treponemal-based assay 2013 79 143,180 10,107,457 1.42
  Test unknown 2011 254 380,835 94,088,412 0.40
WHO  world region
  African Region 2006 633 1,231,508 41,757,009 2.95
  Region of the Americas 2011 276 186,176 25,142,548 0.74
  Eastern Mediterranean Region 2010 130 93,804 16,899,247 0.56
  European Region 2011 193 72,373 65,822,040 0.11
  South-East Asia Region 2008 133 106,639 27,208,629 0.39
  Western Pacific Region 2009 211 186,099 90,801,873 0.20
All data points 2,008 1,576 1,876,599 267,631,346 0.70
Table 1. Adult syphilis prevalence data (1990–2016), available in the Spectrum-STI global database. Notes to 
Table 1: Data available as of 02 May 2018. For WHO world regions, see: (http://www.who.int/about/regions/en/). 
ANC = Antenatal Care. RPR = Rapid plasma reagin. TPHA = Treponema pallidum hemagglutination assay.
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The precision of the prevalence estimates improved as the number of country data points between 2011 and 
2016 increased (Fig. 4; Pearson R2 = 0.05, p = 0.011). Countries with fewer than three data points between 2011 
and 2016 had considerably wider 95% CIs, which reduced the statistical significance of any difference in the 2012 
to 2016 period.
Figure 1. Average number of eligible syphilis prevalence data points, recorded in the Spectrum STI syphilis 
database, grouped by WHO region. Note to Fig. 1: Lines represent linear trend lines fitted through the data 
points for each region.
Figure 2. Spectrum-STI estimations of adult female syphilis prevalence (a) Morocco and (b) Mongolia. Notes 
to Fig. 2: Data shown are after adjustment for diagnostic test performance. Neither country had any data 
included from years 1990–1995; both estimations used data from ANC and general populations only; both 
countries were classified as having a non-substantive prevalence increase over 2012–2016. Solid line = is the 
best estimate (median of 400 bootstraps), dashed lines are the 95% confidence interval.
Figure 3. Spectrum-estimated national syphilis prevalence in 2016 as a function of estimated prevalence in 
2012, and each country’s time trend classification, for 132 countries: (a) Grouped by WHO region. (b) Grouped 
by time trend category. Notes to Fig. 3: The black dotted line indicates equality of prevalence within a country at 
2012 and 2016.
www.nature.com/scientificreports/
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Sensitivity analysis. Altering the eligibility of countries in the trend analysis by restricting the analysis to 
countries with one or more data point post-2011 (Scenario A) had almost no effect on the cross-country median 
prevalences or on the proportion of countries where prevalence decreased (Table 2). Similarly, changing the sta-
tistical model to constrain the extrapolation past the last data point to only one year instead of two years (Scenario 
B) had no discernible impact on the key outcomes.
Reducing the number of years of prevalence data included in the analysis (Scenario C) lowered the 
cross-country median prevalence in 2012 from 0.57% to 0.46% and slightly increased it in 2016 (0.88% to 0.93%). 
The total number of countries with increasing and decreasing trend was similar, although the proportion of 
countries where this increase or decrease was substantive became larger. Similarly, constraining the data used to 
ANC populations, increased the proportion of countries where the trend of increase or decrease was substantive 
(Scenario D).
Trend results were sensitive to restricting the entry criteria to only surveys where blood samples were dual 
test positive (i.e. positive on both treponemal and non-treponemal tests; Scenario E). The total number of coun-
tries in this analysis was 85 and the cross-country median prevalence in 2012 increased from 0.57% (Default 
Scenario) to 0.94%, whilst the median prevalence in 2016 increased slightly from 0.88% to 0.86%. This subset 
of higher-prevalence countries had a larger proportion with a decreasing trend (53%, compared to 41% in the 
default).
Blood donors were not included in the analysis because of their likely non-representativeness of overall pop-
ulations; transfusion services often exclude donors with self-reported risks or observed infections. We did, how-
ever, examine the subset of countries where there were insufficient data for estimation according to the default 
eligibility criteria, but where a time trend could be estimated if we included prevalence data from routine blood 
donor screening34–46 (Scenario F). Thirty-four countries met this criteria and their cross country median preva-
lence was much lower (0.04–0.05% from 2012 to 2016), and the proportion of countries with a decreasing preva-
lence was also lower (29%) than in the default (41%). These were mainly high-income and higher-middle-income 
countries, mostly in the European Region, and secondarily in the Western Pacific and Eastern Mediterranean 
Regions; they were also mostly smaller countries with smaller adult populations somewhat smaller countries with 
adult populations of on average also mainly smaller-populations (SI4 Table).
Discussion
The Spectrum-STI estimation model is a useful tool, developed for national health officials to explore historic 
trends in adult syphilis prevalence to inform and improve their program planning, target-setting and progress 
evaluation in syphilis control and congenital syphilis elimination. The present study is the first attempt to exam-
ine systematically recent trends in the prevalence of syphilis at the national level, and collectively for much of the 
world’s population. The analysis complements previous efforts that looked at trends over time in specific coun-
tries30 or at regional and global levels47,48.
The Spectrum estimates indicate that many countries are making progress in reducing the prevalence of syph-
ilis in adult women. The estimated prevalence in 2016 was lower than in 2012 in 54 of the 132 countries with 
sufficient data to meet our study entry criteria, and in 5 countries this decrease was substantive from a public 
health perspective. In the 78 countries where the prevalence was higher in 2016 than in 2012 the increase was 
substantive in 10. At the current rate of declines only 12 of the 132 countries are on course, assuming this decline 
continues at the same rate, to meet the WHO target of a 90% reduction in the incidence of syphilis in adults from 
2018 to 20301.
Seventy-four countries had insufficient data to meet the criteria for generating a Spectrum estimate. For 34 of 
these, by expanding the study entry criteria to include blood donors, we were able to generate a trend estimate; 
this subset of countries had a much lower prevalence of infection. Of the remaining countries, 20 had at least 
one data point and these had observed prevalences lower than countries in the default and blood donor-based 
Figure 4. Relation between number of national prevalence data points, and precision of point prevalence 
estimates. Notes to Fig. 4: Precision expressed, on the y-axis, as the width of the 95% CI (averaged between 2012 
& 2016) divided by the point estimate. Each dot represents a country with a Spectrum national trend estimate 
based on data from ANC and general populations.
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estimates (SI4). For another 20 countries we were not able to identify any data post-1999 from a study in an ANC 
or general population; these were primarily high-income countries in the European and Eastern Mediterranean 
regions where ANC women are screened for syphilis but the data are either not collated for surveillance purposes, 
or not reported through international mechanisms like the Global AIDS Monitoring system (see SI4 and SI5).
Restricting the analysis to those studies where individuals were tested with both treponemal and 
non-treponemal tests (n = 85) resulted in an increasing proportion of countries with declining rates from 41% to 
53%. This different result is in part due to a selective, higher-prevalence set of countries (with the countries with 
higher prevalence at 2012 more often showing a subsequent decline, Fig. 3b), and it may in part reflect a more 
rigid data set less affected by uncertainties and potential mis-classifications in diagnostics tests and their adjust-
ment factors (which were based on a meta-analysis of studies pre-201428). The larger declines estimated for the 
higher-prevalence countries also illustrate that at regional and global levels syphilis may still be declining, even 
if equal number of countries (but more often, less populous and lower-prevalence countries) showed increasing 
trends.
At a country level the Spectrum-STI syphilis estimates concur with recent historic trend estimates, for those 
few countries with such an independent estimate available30. At regional level, a recent meta-regression of the 
Spectrum database (in a year’s older, less complete version), with data aggregated across countries, estimated 
average proportional annual decline rates over 1990 to 2016 of around 5% for the African Region, 8% for the 
Region of the Americas, 16% for the Eastern Mediterranean Region, 6% for the European Region, 10% for the 
South-East Asian Region and 3% for the Western Pacific Region29, which are consistent with our Spectrum-based 
estimates for countries in these regions. These prior syphilis trend analyses29,30 have generally highlighted a 
declining trend over longer time horizons, reflecting behavioral risk reductions (e.g. increased use of condoms 
and fewer partners)49,50, improvements in the coverage of ANC-based syphilis screening and treatment as well 
as treatment of partners48, and increased use of antibiotics such as oral penicillin, tetracyclines and macrolides, 
commonly prescribed for skin, respiratory, and other non STI-infections, which have activity against syphilis as 
well51. This includes over 741 million doses of azithromycin administered as part of mass trachoma treatment 
campaigns since 1999 in trachoma-endemic countries52.
Our analysis shows that in many other, mainly lower-prevalence countries, syphilis prevalence tended to 
increase from 2012 to 2016. Possible reasons for recent increases in these countries may include: saturation 
of prior declines associated with roll-out of ANC-based services; fatigue with safer sex and behaviour-based 
HIV prevention, possibly in response to the rapid expansion of access to HIV treatment drugs; shifts from con-
dom usage to longer-term hormonal contraception53; and the recent global shortage of benzathine-penicillin 
used as first-line treatment for syphilis54. Furthermore, measuring prevalence using RPR/TPHA dual testing or 
RPR-based testing may obscure recent declines owing to the time lag for a person to test RPR negative after treat-
ment. For example, if the median time for RPR to sero-revert after treatment is 1 to 2 years55–57 real prevalence 
reductions will only become apparent after a 1 to 2 year delay.
Limitations. The quality of statistical trend estimates reflects the quantity, quality and representativeness of 
the input data. The Spectrum syphilis database draws on data from a variety of sources including the Global AIDS 
Monitoring System and is the most global comprehensive database on syphilis now. Experience from country 
workshops22,25–27, however, suggests that there are additional data available within countries. Country outreach 
can also improve data quality, for example, by providing information on the specific diagnostic test types.
The Spectrum estimates were based on data primarily from ANC women (79% of data points, 63% of tests). 
The focus on data from ANC women means we may be over-estimating the prevalence in the general female 
Scenario
Countries 
included
Median 
prevalence, 2012
Median 
prevalence, 2016
Countries with prevalence trend from 2012 to 2016
Substantive 
increase
Non-substantive 
increase
Non-substantive 
decrease
Substantive 
decrease
Default estimates 132 0.57% 0.88% 14 (11%) 64 (48%) 48 (36%) 6 (5%)
A. At least one data point from 2012 or later 129 0.55% 0.87% 14 (11%) 62 (48%) 47 (36%) 6 (5%)
B. More restrained time trends: extrapolate past the last 
year with national data, for 1 year instead of 2 years 132 0.57% 0.92% 13 (10%) 65 (49%) 48 (36%) 6 (5%)
C. Restrict data to 2005 and later (instead of 1990) 130 0.46% 0.93% 17 (13%) 61 (47%) 44 (34%) 8 (6%)
D. ANC (survey & routine screening) data only 131 0.56% 0.90% 18 (14%) 62 (47%) 43 (33%) 8 (6%)
E. Syphilis infections positive on both treponemal and 
non-treponemal tests 85 0.94% 0.86% 8 (9%) 32 (38%) 42 (49%) 3 (4%)
F. Countries not included in default but made eligible 
for trend analysis by adding blood donor data 34* 0.04% 0.05% 3 (9%) 21 (62%) 9 (26%) 1 (3%)
Table 2. Sensitivity analysis: Spectrum-estimated syphilis prevalence in 132 countries, under varying scenarios 
of data included and modelling assumptions. Notes to Table 2. The presented medians, which are unweighted, 
should not be interpreted as indicative of global burden trends, as global trends depend on national population 
sizes. Scenario F presents 34 countries that were not included in the default analysis. In none of the 7 scenarios, 
none of the countries and none of the years between 2012–2016 was the 20% maximum value imposed on 
estimated prevalence ever reached, neither in the best estimate (i.e. the median of 400 bootstraps) nor in the 
upper-bound limit of each corresponding 95% confidence interval.
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population, as ANC women are sexually active and younger. Also recent syphilis declines may be larger in ANC 
populations than the overall adult population, as multiparous pregnant woman may have been diagnosed and 
treated in an earlier pregnancy. The HIV field has noted that ANC sentinel surveys and ANC-based HIV screen-
ing historically over-estimate HIV prevalence compared to general population surveys, as sentinel sites and rou-
tine screening were usually first established in urban, higher-risk areas58,59; however, syphilis prevalence has not 
consistently been higher in urban areas, and may in fact be higher in underserved rural populations, as a function 
of access to health care and exposure to antibiotics.
Our analysis included a small number of data points from community-based studies in men, and assumed a 
male-to-female ratio of 1 to 1, based on a recent global meta-analysis29. Removing these data points had almost no 
impact on the results (sensitivity analysis, Scenario D). The lack of male data, however, is a considerable challenge 
when generating national syphilis burden estimates. The few countries with data highlight that there is consider-
able variation in the male-to-female ratio between countries and within countries.
The Spectrum-STI model is a work in progress and, like the Spectrum HIV models, is being refined as 
more data become available. The current version of the model is focused on modeling trends over time in the 
general population—data from populations at higher risk of infection are not incorporated. A new variant of 
Spectrum-STI is under development that will include sub-group estimates such as for FSW and MSM, incor-
porating data from other sources like integrated bio-behavioural surveillance surveys (see26 for an example of 
sub-groups estimation). This will make it possible to remove the 10% adjustment factor for high-risk populations 
from the current version of Spectrum-STI. For Morocco, Mongolia and Colombia, comparative prevalences of 
syphilis in FSW relative to Spectrum-STI estimates for women, combined with national estimates of numbers of 
FSWs22,25,27, suggested that a 10% uplift in prevalence was a reasonable adjustment for them. However, contribu-
tions of higher-risk populations vary across countries and may be higher, in countries with low STI prevalences26. 
Several higher-income countries60,61 as well as China62 recently recorded rising syphilis prevalence in MSM, 
which may be driving reversals from past prevalence declines among men and in the general adult population63. 
Other refinements that could be considered for future Spectrum versions include sub-national disaggregation 
and looking in more detail at age. For large countries like India, Indonesia, China, Nigeria and the Democratic 
Republic of the Congo, national aggregation is a limitation62,64.
Conclusion
Spectrum-STI provides a useful tool for countries to monitor trends over time in the prevalence of syphilis. The 
quality and usefulness of these estimates reflects both the quality and quantity of the data available. As countries 
improve their syphilis surveillance, estimations should also improve and countries then should be in a better 
position to set targets for syphilis control and elimination, and to mobilize funding to expand access to existing 
services and launch and intensify complementary services, such as screening and treatment for key populations. 
The trend analysis presented in this paper suggests that whilst the prevalence of syphilis fell in a number of coun-
tries between 2012 and 2016, the prevalence increased in more countries than it fell. This highlights the need to 
intensify efforts to improve syphilis surveillance and control if countries are to meet the WHO’s syphilis reduction 
targets for 2030.
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